Amylyx Pharmaceuticals, Inc. (AMLX) Cash Flow Statement

The OCF/NI ratio has fluctuated wildly, from 0.00 in 2024Q1 to 1.57 in 2024Q4, reflecting the lumpy nature of restructuring payments and trial wind-down costs. The recent quarters show a more stable ratio around 0.7-0.9, suggesting that cash burn is now more aligned with the reported net loss, but the absence of revenue means this is purely a measure of cash consumption, not earnings quality.

The FCF trajectory shows a clear downward trend in cash burn, but it remains substantial relative to the $226.6M cash balance. With no revenue, the FCF margin is undefined, and the company is entirely dependent on its cash reserves to fund operations. The stabilization suggests management has successfully downsized, but the runway is still limited to roughly five quarters at the current burn rate.

The near-zero CapEx underscores that AMLX is no longer investing in commercial manufacturing or infrastructure, consistent with its pivot back to a pure R&D organization. This low capital intensity means the primary cash drain is operating expenses, particularly R&D and SG&A, rather than fixed asset replacement. Investors should monitor whether any future CapEx is needed for clinical trial expansion or if the company can maintain this lean asset base.

The working capital adjustments are not indicative of operational efficiency but rather the unwinding of commercial operations. The positive swings in some quarters suggest cash inflows from settling liabilities or collecting receivables, while negative swings reflect payments for restructuring and trial obligations. As the company stabilizes into a clinical-stage entity, these swings should diminish, but they currently add noise to the cash flow analysis.

The absence of any capital returns is expected for a company in a cash preservation mode. The only deployment is operational burn, which is necessary to fund the ORION and HELIOS trials. The lack of acquisitions or debt paydown further confirms that management is hoarding cash to extend the runway. Investors should watch for any strategic deployment, such as a partnership or licensing deal, that could alter this conservative stance.

The gap between net income and operating cash flow is substantial, with non-cash items like stock-based compensation and depreciation totaling roughly $60M over the period. This divergence suggests that the economic cash drain is less severe than the accounting losses, but it does not change the fact that the company is consuming cash at an unsustainable rate. The cumulative cash burn of $359M highlights the urgency of reaching clinical milestones or securing additional financing.